CNS Drugs

, Volume 26, Issue 1, pp 79–91 | Cite as

Pharmacokinetics, Drug Interactions and Exposure-Response Relationship of Eslicarbazepine Acetate in Adult Patients with Partial-Onset Seizures

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses
  • Amilcar Falcão
  • Eliane Fuseau
  • Teresa Nunes
  • Luis Almeida
  • Patricio Soares-da-Silva
Original Research Article

Abstract

Background: Eslicarbazepine acetate (Zebenix®) is a voltage-gated sodium channel blocker approved in 2009 by the European Medicines Agency as adjunctive therapy in adults with partial-onset seizures, with or without secondary generalization.

Objectives: The objectives of the current population pharmacokinetic (PK) and PK/pharmacodynamic analyses were to characterize the population PK of eslicarbazepine (the main active metabolite of eslicarbazepine acetate), to evaluate the influence of patient factors and concomitant antiepileptic drugs (AEDs) on the PK variability of eslicarbazepine, to assess the effect of eslicarbazepine acetate on the PK of concomitant AEDs and to investigate the relationship between eslicarbazepine systemic exposure and eslicarbazepine acetate antiepileptic activity in patients with partial-onset seizures uncontrolled with one to three AEDs.

Methods: Sparse plasma concentrations of eslicarbazepine and concomitant AEDs, along with efficacy data, were obtained from 641 patients enrolled in eslicarbazepine acetate phase III studies. Data were analysed using nonlinear mixed-effect modelling methods. Most analyses used a model using log-transformed data from trough concentration (minimum steady-state plasma concentration during a dosage interval [Cmin,ss]). The model estimated the apparent total body clearance from plasma (CL/F), which is sufficient to predict average plasma concentrations at steady state (Cav,ss). After the final model was validated, individual concentrations at steady state were predicted, and exposure parameters (area under the plasma concentration-time curve over 24 hours, Cmin,ss and Cav,ss) for a one-compartmental model with first-order elimination were calculated.

Results: Eslicarbazepine CL/F was affected by bodyweight, dose of carbamazepine (DCAR) and co-administration of barbiturates or phenytoin (AEDPB), as predicted by the equation CL/F = (2.36 + 0.00149 · DCAR + 1.41 · AEDPB) · (weight/70)0.75, which means that CL/F is 2.36L/h for a subject with a bodyweight of 70 kg and without concomitant carbamazepine and barbiturates/phenytoin. Concomitant use of lamotrigine, valproic acid, topiramate, gabapentin, clobazam and levetiracetam showed no effect on the exposure to eslicarbazepine. Inter-individual variability of eslicarbazepine CL/F was 44% and the residual error (intra-subject variability) was proportional to the log of concentrations, with a coefficient of variation of 6%. Age, ethnicity, sex and creatinine clearance did not affect eslicarbazepine CL/F. Eslicarbazepine acetate did not affect the CL/F of clobazam, gabapentin, phenytoin, phenobarbital, levetiracetam and valproic acid. Eslicarbazepine acetate slightly increased the CL/F of carbamazepine (up to 14%), lamotrigine (up to 12%) and topiramate (up to 16%). The antiepileptic effect of eslicarbazepine acetate, as assessed by a decrease in seizure frequency, increased with the increase of eslicarbazepine acetate dose and eslicarbazepine concentrations. The concomitant administration of other AEDs did not affect the eslicarbazepine acetate exposure-response relationship.

Conclusions: The magnitude of the effect of eslicarbazepine acetate on the CL/F of the concomitant AEDs assessed appears to be not clinically relevant and does not justify the need for dose adjustment in most patients. A continuous dose-response relationship was observed between eslicarbazepine concentrations and seizure frequency reduction, which was not affected by concomitant AEDs.

References

  1. 1.
    Almeida L, Bialer M, Soares-da-Silva P. Eslicarbazepine acetate. In: Shorvon S, Perucca E, Engel J, editors. The treatment of epilepsy. 3rd ed. Oxford: Blackwell Publishing, 2009: 485–98CrossRefGoogle Scholar
  2. 2.
    Almeida L, Potgieter JH, Maia J, et al. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 2008 Mar; 64(3): 267–73PubMedCrossRefGoogle Scholar
  3. 3.
    Maia J, Almeida L, Falcão A, et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther 2008 Mar; 46(3): 119–30PubMedGoogle Scholar
  4. 4.
    Elger C, Bialer M, Cramer JA, et al. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007 Mar; 48(3): 497–504PubMedCrossRefGoogle Scholar
  5. 5.
    Elger C, Halasz P, Maia J, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009 Mar; 50(3): 454–63PubMedCrossRefGoogle Scholar
  6. 6.
    Ben-Menachem E, Gabbai AA, Hufnagel A, et al. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res 2010 Mar 16; 89(2-3): 278–85PubMedCrossRefGoogle Scholar
  7. 7.
    Gil-Nagel A, Lopes-Lima J, Almeida L, et al. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009 Nov; 120(5): 281–7PubMedCrossRefGoogle Scholar
  8. 8.
    Halasz P, Cramer JA, Hodoba D, et al. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia 2010 Oct; 51(10): 1963–9PubMedCrossRefGoogle Scholar
  9. 9.
    Boeckman AJ, Sheiner LB, Beal SL. NONMEM users guide. San Francisco (CA): NONMEM Project Group, 1992 and 1998Google Scholar
  10. 10.
    Beal S, Sheiner L. NONMEM users guide. San Francisco (CA): University of California, 1998Google Scholar
  11. 11.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41PubMedCrossRefGoogle Scholar
  12. 12.
    Bialer M. Oxcarbazepine: chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson R, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott, 2002: 459–65Google Scholar
  13. 13.
    Flesch G, Czendlik C, Renard D, et al. Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine. Drug Metab Dispos 2011 Jun; 39(6): 1103–10PubMedCrossRefGoogle Scholar
  14. 14.
    Almeida L, Nunes T, Sicard E, et al. Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurol Scand 2010 Apr; 121(4): 257–64PubMedCrossRefGoogle Scholar
  15. 15.
    Nunes T, Sicard E, Almeida L, et al. Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Curr Med Res Opin 2010 Jun; 26(6): 1355–62PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Amilcar Falcão
    • 1
    • 2
  • Eliane Fuseau
    • 3
  • Teresa Nunes
    • 4
  • Luis Almeida
    • 5
  • Patricio Soares-da-Silva
    • 4
    • 6
  1. 1.Faculty of PharmacyUniversity of CoimbraCoimbraPortugal
  2. 2.4Health ConsultingCantanhedePortugal
  3. 3.EMF ConsultingAix-en-ProvenceFrance
  4. 4.Department of Research and DevelopmentBIAL-Portela & Co. S.A., A Av. da Siderurgia NacionalS. Mamede do CoronadoPortugal
  5. 5.Health Sciences DepartmentUniversity of AveiroAveiroPortugal
  6. 6.Department of Pharmacology and Therapeutics, Faculty of MedicineUniversity of PortoPortoPortugal

Personalised recommendations